For the Inventor, By the Inventor

Enter assignee name

Barcelona, Spain

Palobiofarma S.l.

USPTO Granted Patents = 12

CIPO Patents = 23

EPO Patents = 14

Forward Citations = 17

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

Juan Camacho Gómez (6 out of 9 patents)

Julio Cesar Castro-Palomino Laria (6 out of 16 patents)

Juan Alberto Camacho Gomez (4 out of 4 patents)

4. Julio Cesar Castro Palomino Laria (3 out of 18 patents)

5. Weiyong Kong (2 out of 5 patents)

6. Sanela Bilic (2 out of 2 patents)

7. John Scott Cameron (2 out of 4 patents)

8. Danny Roland Howard, Jr (2 out of 2 patents)

9. Kai Cui (2 out of 5 patents)

10. Abdelaziz El Maatougui (1 out of 1 patent)

11. Adela Mendoza Lizaldez (1 out of 1 patent)

12. Julio Castro-Palomino Lária (1 out of 1 patent)

13. Lyhen Gonzalez Lio (1 out of 1 patent)

14. Julio Castro Palomino Laria (1 out of 3 patents)

15. Danny Roland Howard (0 patent)

12 patents: Sort by Forward Citations

1. 12384754 - Cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid (2025-08-12),

2. 11654144 - Crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1- yl)pyrimidin-4-amine and new salts (2023-05-23),

3. 11078191 - 1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)pyrimidin-2-yl)-1H-pyrazol-4-ol and use thereof in the treatment of cancer (2021-08-03),

4. 10933064 - Crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine and new salts (2021-03-02),

5. 10744125 - Adenosine A3 receptor modulators (2020-08-18),

6. 10583127 - Amine salt of (1R, 3S)-3-(5-cyano-4-phenyl-1,3- thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid (2020-03-10),

7. 10561653 - 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer (2020-02-18),

8. 10253017 - [object Object] (2019-04-09),

9. 10238637 - Modulators of the adenosine A3 receptors (2019-03-26),

10. 9447095 - Pyrimidine derivatives as phosphodiesterase 10 inhibitors (PDE-10) (2016-09-20),

11. 8796284 - [object Object] (2014-08-05),

12. 8410282 - [object Object] (2013-04-02),

Palobiofarma S.L. is a pharmaceutical company dedicated to the research, development, and commercialization of innovative drugs in the field of oncology. With a strong focus on precision medicine, Palobiofarma aims to provide effective and personalized treatments for cancer patients. Their dedicated team of researchers and scientists work closely to discover breakthrough therapies that target specific molecular drivers of tumors. With a commitment to improving patient outcomes, Palobiofarma strives to bring new and promising therapies to market, ultimately contributing to the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

12 Patents

#50 in Barcelona

#170 in Spain

#46,630 in the World

Barcelona, Spain

Palobiofarma S.l.

Forward Citations = 17

30 inventors:

Juan Camacho Gómez (6 out of 9 patents)

Julio Cesar Castro-Palomino Laria (6 out of 16 patents)

Juan Alberto Camacho Gomez (4 out of 4 patents)

4. Julio Cesar Castro Palomino Laria (3 out of 18 patents)

5. Weiyong Kong (2 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…